Third-line Treatment of Gefitinib in NSCLC Patients Who Had Received First-line Gefitinib With EGFR 19del/L858R Mutation and Tumor Progression After the Second-line Chemotherapy: a Single-arm, Prospective, Multi-center and Exploratory Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jun 2017 Primary endpoint (Disease Control Rate (DCR)) has been met, as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 23 Feb 2017 Planned End Date changed from 1 Jun 2016 to 31 Dec 2017.